Objective:To investigate the efficacy and safety of S1

oxaliplatin

irinotecan and leucovorin combination chemotherapy in advanced gastric carcinoma.Methods:48 patients with advanced gastric cancer were enrolled.Patients receiving S1

at 80 mg/m2

was orally administered twice daily for 2 weeks

followed by a drug-free interval of 1 week(one cycle).Concurrently

Irinotecan(150 mg/m2) and leucovorin(200 mg/m2) were given on day 1

twice daily for two weeks

followed by oxaliplatin 130 mg/m2.The chemotherapy was repeated every 4 weeks.All patients received 2 cycles at least.Efficacy and toxicities were evaluated according to the RECIST 1.1 standard.Results:All the 48 patients were assessable for response.There were 5(10.4%) complete remission(CR)

23(47.9%) partial remission(PR)

12(25.0%) stable disease(SD)

and 8(16.7%) progression disease(PD).The overall response rate was 58.3%.The disease control rate(DCR) was 83.3%.Median time to progression(TTP) and median survival time(MST) were 8.9 and 12.3 months

respectively.The major toxicities were neurosensory abnormity

leukopenia

nausea

hematologic toxicity and vomiting.Conclusion:The combination of S1

oxaliplatin

irinotecan and leucovorin has good clinical activity with acceptable toxicity in patients with advanced gastric cancer.